The objective of this article is to review the recently published literature on the use of robotic surgery in the management of gynecologic malignancies.
INTRODUCTION
The introduction of robotic-assisted surgery has had a significant impact on the surgical approach to gynecologic malignancies, changing the patterns of practice within the gynecologic oncology community. Over 1400 da Vinci robotic surgical systems (Intuitive Surgical, Inc., Sunnyvale, CA) have been installed in the US, serving both academic and community hospital systems. Because of this rapid growth and acceptance of this technology, over 1200 gynecologic surgeons have been trained to use the da Vinci robotic system since it was first approved in 2005. Its acceptance stems from the added advantages offered by it to the surgeons compared to traditional laparoscopy. These benefits include three-dimensional stereoscopic vision, wristed instrumentation that allows better dexterity and precision, thus enabling robotic-assisted surgery to become more widely embraced by gynecologic oncologists for the treatment and staging of gynecologic malignancies.
Despite being increasingly used for the management of early-stage cervical, endometrial, and ovarian cancers, there have been frequent discussions and debates about the limitations of robotic surgery, including cost, lack of haptic feedback, potential negative impact on fellowship training, and lack of prospective randomized trials showing benefit of robotic surgery. However, as with other tools for minimally invasive surgery, broad-based use of robotic surgery throughout the community has led to its acceptance into standard practice in gynecologic oncology [1 & ]. The purpose of this review is to summarize the recent literature on the use of robotic surgery in the management of gynecologic malignancies.
CERVICAL CANCER
The use of minimally invasive surgical techniques for the treatment of early-stage cervical cancer (stage IA2 and IB1) has gained popularity over the past decade in efforts to reduce morbidity while maintaining surgical outcomes. The laparoscopic approach to radical hysterectomy and radical trachelectomy is not as widely accepted due to the complexity of the procedure and technical challenges using two-dimensional instruments leading to prolonged learning curves and operating times. Since the first published report of robotic radical hysterectomy in 2006 [2] , several publications have evaluated the safety, efficacy, and feasibility of robotic-assisted laparoscopic radical hysterectomy and pelvic lymphadenectomy to treat early-stage cervical cancer. In the first pilot casecontrol series comparing robotic and laparoscopic radical hysterectomy and bilateral pelvic lymphadenectomy, there was no difference in operative time, number of lymph nodes excised, and length of parametrial tissue excised between the two groups. However, there was significantly less blood loss (71 vs. 160 ml) and shorter length of hospital stay (4 vs. 8 days) in the robotic-assisted group (P < 0.05) [3] .
Over the past 5 years, over 300 robotic-assisted laparoscopic radical hysterectomies have been reported with the majority of studies supporting the safety and feasibility of the technique. One of the largest early series included a case series of 80 patients with early-stage cervical cancer or stage II endometrial cancer by Persson et al. [4] that prospectively collected short and long-term follow up data. This study demonstrated decreasing complications over time as more procedures were performed. Despite this, over 40% of patients had some minor adverse event, including 6% rate of vaginal cuff dehiscence and 14% that required 60 days or more to resume spontaneous voiding [4] . Boggess et al. [5] also published a large singleinstitution study of over 50 patients undergoing robotic radical hysterectomy, demonstrating decreased blood loss, operative time, and hospital stay compared to a cohort undergoing open radical hysterectomy. In 2009, Lowe et al. [6] published a multicenter case series of 42 patients undergoing robotic radical hysterectomy that similarly showed acceptable operative outcomes without an increased complication rate. There have been four studies comparing robotic-assisted radical hysterectomy to traditional laparoscopic and open radical hysterectomy, all producing similar results [7] [8] [9] [10] . Magrina et al. [7] were the first to compare the three different surgical approaches in 2008. Mean operative times for patients in the robotic, laparoscopic, and open cohorts were 190, 220, and 167 min, respectively; mean estimated blood loss was 133, 208, and 443 ml, respectively; and mean length of hospital stay was 1.7, 2.4, and 3.6 days [7] . Soliman et al. [10] [10] .
Despite many published retrospective studies supporting equivalency of a minimally invasive surgical approach to radical hysterectomy, there has been no completed prospective comparison that is adequate to classify robotic or laparoscopic radical hysterectomy as an equivalent surgical approach to open radical hysterectomy. A multicenter phase III randomized clinical trial comparing robotic or laparoscopic radical hysterectomy with abdominal radical hysterectomy in patients with early-stage cervical cancer is currently underway. The primary endpoints include rate of enrollment and equivalence with respect to disease-free survival. Secondary endpoints include treatment-related morbidity, cost and cost-effectiveness, patterns of recurrence, quality of life, pelvic floor function, feasibility of intraoperative sentinel lymph node sampling, and overall survival (OS) [11] . Cantrell et al. [12] recently published their single-institution 3-year outcomes of 71 patients undergoing robotic radical hysterectomy. With a median follow-up of 12.2 months, they reported a 94% progression-free survival (PFS) and OS at 36 months. Compared to a historical cohort of traditional laparotomy patients, there was no significant difference in PFS or OS [12] .
With the advantages of surgical instrumentation with the da Vinci robotic surgical system, a minimally invasive surgical option for fertility-preserving techniques such as radical trachelectomy appears to be a feasible alternative to an open or vaginal approach. Although there have been reports
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of laparoscopic radical trachelectomy [13] , this approach has not been widely accepted due to the complexity of the procedure, rigid instrumentation, and advanced skill of the surgeon. In the largest series to date published by Nick et al. [14] , outcomes for 37 patients undergoing either open (25 patients) or robotic (12 patients) radical trachelectomy were retrospectively analyzed. Five patients (one open and four robotic) underwent conversion to radical hysterectomy due to close endocervical margins. Robotic radical trachelectomy was associated with less blood loss (62 vs. 300 ml) and decreased hospital stay (1 vs. 4 days), with no difference in operative time or histopathologic outcomes. Rates of serious morbidities related to surgery were comparable between the two groups [14] .
There have also been published series using minimally invasive surgical techniques in locally advanced and recurrent cervical cancer. Failure to detect nodal metastases in patients with locally advanced cervical cancer (IB2-IVA) can lead to suboptimal treatment. A recent prospective study found that of 27 patients with positive pelvic but negative para-aortic lymph nodes on PET/computed tomography (CT), 6 (22%) had histopathologically positive para-aortic lymph nodes. Eleven (18%) patients had a treatment modification based on surgical findings [15] . An extraperitoneal approach to para-aortic lymphadenectomy overcomes the technical limitations of a transperitoneal approach and decreases the risk of postoperative adverse events including ileus and intestinal obstruction. The safety and feasibility of the laparoscopic extraperitoneal approach have been described in multiple studies [15, 16] ; however, robotic technology provides additional advantages with instrumentation, particularly when working in a limited surgical field such as during an experitoneal para-aortic lymphadenectomy. Vergote et al. [17] reported the first series of robotic extraperitoneal para-aortic lymphadenectomy in patients with advanced cervical cancer, and concluded the robotic procedure was technically easier than the laparoscopic approach. The largest series of 15 patients undergoing robotic extraperitoneal para-aortic lymphadenectomy was recently reported, and retrospectively compared to 24 patients undergoing a robotic transperitoneal para-aortic lymphadenectomy. There was no difference in operative time (202 vs. 164 min), estimated blood loss (71 vs. 155 ml), nodal count (17 vs. 13 nodes), or hospital stay (2.6 vs. 3.1 days) in those patients undergoing a robotic extraperitoneal vs. transperitoneal approach, respectively. However, the authors commented on limited space for da Vinci robotic arm placement, frequent instrument collisions, and risk of great vessel injury [18] .
Advanced robotic surgery has been reported in several case series for use in pelvic exenteration procedures for locally recurrent gynecologic malignancies [19] [20] [21] [22] . Most of these cases also used a small laparotomy to complete the urinary conduit after the robotic-assisted resection was complete [19] [20] [21] . Although feasibility has been demonstrated, further information is needed for oncologic outcomes, perioperative outcomes, and quality of life prior to recommending the robotic-assisted approach to traditional laparotomy.
ENDOMETRIAL CANCER
Minimally invasive surgery is now accepted as an integral surgical tool in the treatment of endometrial cancer. The largest prospective comparison of laparoscopy to laparotomy for endometrial cancer staging, the Gynecologic Oncology Group (GOG) Lap-2 study, confirmed the feasibility and improved short-term surgical safety associated with laparoscopic staging for endometrial cancer compared to the same procedure performed by laparotomy [23] . This group recently reported a 3-year recurrence rate of 11.4% with laparoscopy and 10.2% with laparotomy. Five-year OS rates were 89.8% for both arms. This suggests that laparoscopic staging did not adversely affect survival in patients with endometrial cancer [24 && ]. Robotic-assisted laparoscopy overcomes the technical obstacles that many surgeons experience with traditional laparoscopy, especially in an obese population. A number of retrospective studies comparing robotic or laparoscopic hysterectomy and staging with laparotomy have been performed. The largest series to date is a systematic review of eight comparative studies with a total of 1591 patients (589 robotic, 396 laparoscopic, 606 laparotomy cases). The authors found estimated blood loss was lower for robotic compared to laparoscopy (P ¼ 0.001) or laparotomy (P < 0.005) cases; however, operative times for robotic and laparoscopy cases were similar, but longer than that for laparotomy cases (P < 0.005). There was no difference in nodal counts or perioperative complications between the three groups. There was no difference in conversion to laparotomy between the robotic (4.9%) and laparoscopic (9.9%, P ¼ 0.06) groups [25] .
Although prospective trials evaluating the use of robotics in endometrial cancer staging are lacking, many single institutions have reported large case series showing benefits using the robotic platform. Paley et al. [26] reported surgical outcomes from their first 377 consecutive robotic endometrial cancer staging surgeries from a single institution. Compared with open staging, women undergoing robotic endometrial cancer staging had lower blood loss (47 vs. 198 ml; P < 0.0001), shorter hospitalization (1.4 vs. 5.3 days; P < 0.0001), higher lymph node counts (15.5 vs. 13.1 nodes; P ¼ 0.007), and fewer major complications (6.4 vs. 20.6%; P < 0.0001). The most significant reduction was in the incidence of wound separation or dehiscence, infectious complications, and ureteral injury or acute renal failure in the robotic surgery group. The authors estimate that the incorporation of robotic surgery into their minimally invasive surgery program was most significant for endometrial cancer patients with a 12.5-fold increase in endometrial cancer patients receiving staging via a robotic minimally invasive surgical approach [26] . Many other single-institution minimally invasive surgical programs have reported a similar experience [27] .
Robotic surgery for endometrial cancer staging has been rapidly incorporated into many gynecologic oncology practices across the country, not only in large academic institutions, but also in community practices. The learning curve has been described as faster for robotic hysterectomy and lymphadenectomy compared to laparoscopic hysterectomy and lymphadenectomy with comparable adequacy of surgical staging between the two surgical methods [28] . Recent studies have also shown advantages of robotic surgery in endometrial cancer staging procedures in obese patients when compared to laparotomy [29] and laparoscopy [30] in terms of blood loss, transfusion rates, length of hospital stay, wound complications, and rate of conversion to laparotomy [29, 30] . Whereas comprehensive lymphadenectomy has been shown to be an important part of endometrial cancer staging, there has been recent interest in sentinel lymph node mapping to reduce the risk of perioperative and long-term complications that can be associated with lymphadenectomy. New developments in the robotic optical system include the near-infrared fluorescent imaging to assist in sentinel lymph node mapping with the use of indocyanine green fluorescing dye. Early studies have demonstrated its safety and feasibility; however, larger case series and prospective trials are needed [31] .
Altogether, it appears that robotic surgery may be equivalent, and in some situations, may offer an advantage over laparoscopy in patients undergoing endometrial cancer staging. Prospective trials are needed to assess not only clinical outcomes but also cost-effectiveness of each surgical modality.
OVARIAN CANCER
Given the expanding interest of use of minimally invasive surgical techniques in staging of other gynecologic malignancies, there is also interest in using this approach in the management of ovarian cancer. Comprehensive surgical staging for ovarian cancer, however, requires meticulous exploration of the peritoneal cavity. Some have argued that robotic-assisted laparoscopy is neither well tolerated nor feasible given the limited range of motion, visibility, and haptic sensation. Minimally invasive surgery for advanced ovarian cancer with diffuse gross metastatic disease is not recommended due to the low likelihood of optimal tumor debulking and increased risk of surgical complication [32] .
The use of robotics in ovarian cancer staging has primarily been limited to borderline and early-stage ovarian cancers. Complete surgical staging of borderline ovarian tumors is recommended secondary to the risk of underdiagnosis of invasive ovarian cancer on frozen section. The largest retrospective study to date, a French multicenter study, compared 107 patients who underwent laparoscopic management of a borderline ovarian tumor to 209 patients who underwent laparotomy. They found a higher rate of conservative surgery and incomplete surgical staging in the laparoscopy group; however, there was no difference in the overall recurrence rate (12.1 vs. 9.1%) [33] . Comprehensive surgical staging is recommended for early-stage invasive ovarian cancer to provide adequate prognostic information and for treatment planning. Several retrospective studies have demonstrated the safety and feasibility of laparoscopic surgical staging of early-stage ovarian cancer without diminished quality of staging or increased risk of recurrence [34] [35] [36] .
Given the technological advantages of robotic surgery, the early experience of using robotic surgery in the management of advanced ovarian cancer has been reported. Magrina et al. [37] performed a retrospective case-control analysis of 25 patients undergoing primary surgical debulking with the robotic approach, compared to 27 patients treated by laparoscopy, and 119 patients treated by laparotomy. Sixty to seventy-five percent of patients had stage III to IV disease in the robotic and laparoscopy groups, respectively. Patients were subdivided according to extent of surgery and number of procedures required to achieve adequate cytoreduction. Complete cytoreduction was defined as no visible residual disease at the end of surgery. There was a significant increase in mean operative time among the robotics cohort (315 min), compared to laparoscopy (254 min) or laparotomy (261 min; P ¼ 0.009). However, the robotics group had less blood loss and shortest mean hospital stay compared to laparoscopy or laparotomy. Complete debulking was achieved in 84% of patients in the robotic group, 93% in the laparoscopy group, and 56% in the laparotomy group (P < 0.001). There was no difference in OS at 3 years amongst the three groups. The authors concluded that robotics or laparoscopy is preferable to laparotomy for ovarian cancer patients requiring primary tumor excision along with one additional major procedure. Laparotomy is preferred for those patients requiring two or more additional major procedures [37] . These data, however, must be analyzed carefully due to the retrospective nature and the inherent patient selection bias in choosing patients for each surgical method.
Other concerns with the use of minimally invasive surgery in gynecologic malignancies, especially ovarian cancer, are port-site metastases, risk of tumor cyst rupture and peritoneal seeding, and effect of CO 2 pneumoperitoneum on tumor growth. The incidence of port-site metastases has been evaluated in several retrospective series, and reported as 1-2%. The authors from Memorial Sloan Kettering Cancer Center identified port-site metastasis in 20 of 1694 patients (1.18%) with malignant intraperitoneal disease undergoing laparoscopy. Fifteen of the 20 patients with port-site metastases had a diagnosis of fallopian tube or ovarian cancer [38] . A similar rate of port-site metastases was recently reported in a robotic cohort of 1.1% [39] . However, the development of port-site metastases has not been shown to affect OS [40] . Compared to laparotomy, laparoscopy has been associated with a higher incidence of cyst rupture during adnexal surgery, which could potentially upstage a patient with ovarian cancer, and adjuvant treatment would be required. Vergote et al. [41] found that intraoperative cyst rupture in stage I ovarian cancer was a strong predictor of decreased PFS. Therefore, appropriate patient selection, meticulous surgical technique, and the use of an endobag for tissue extraction are essential to reduce the risk.
COST ANALYSIS OF ROBOTIC SURGERY
One of the biggest arguments against adoption of robotic technology has been the high direct and indirect costs associated with the robotic surgical system. The robotic surgical systems have a fixed cost of between $1.5 and $1.75 million and annual maintenance fees of approximately $140 000. Other costs to consider when comparing robotics to other surgical approaches are costs of OR supplies, disposable equipment, operating and recovery room time, physician fees, and hospital room and board. Additionally, costs due to complications, care-giving, and lost productivity associated with recovery should also be considered. Barnett et al. [42] recently published clinical data to build decision models to compare costs of robotic, laparoscopic, and open surgery for endometrial cancer, and identify important factors contributing to cost differences. For the societal perspective model, caregiver/lost productivity costs associated with recovery time were also incorporated. The authors found that minimally invasive procedures are less costly than open procedures when the costs associated with hospital stay and recovery time are incorporated. In both the societal and hospital model, the traditional laparoscopic technique remained the least expensive method. The most important factor driving the relative costs in each model was the time to return to full activity and the cost of disposable equipment [42] . A retrospective database study of the cost associated with robotic vs. laparoscopic staging procedures for endometrial cancer was recently analyzed. All cost data were abstracted from International Classification of Diseases Ninth Revision (ICD-9) codes. The mean cost of robotic hysterectomy was $10 618 compared to $8 996 for laparoscopic hysterectomy (P < 0.001), and on multivariate analysis, robotic hysterectomy was significantly more costly [$1291; 95% confidence interval (CI) $985 to $1597]. Both procedures were associated with low overall morbidity [43 & ]. Even though laparoscopy is less costly, surgeon preferences for robotics may allow some women to undergo a minimally invasive procedure for their gynecologic malignancy, who may otherwise have undergone laparotomy. Despite the existence of unique diagnosis and procedure codes for robotic-assisted procedures, there is no higher reimbursement rate to date for robotic-assisted procedures from US Medicare or private insurers. In a recent review of hospital billing and reimbursement from a single institution recently published by Venkat et al. [44 & ], hospital charges for robotic endometrial cancer staging surgery was higher compared to laparoscopy ($63 266 vs. $55 130; P ¼ 0.04). However, reimbursement to the hospital, surgeon, and anesthesiologist was not significantly different between the two surgical approaches [44 & ]. Altogether, the increasing use of the robotic system by gynecologic oncologists nationwide may have a favorable impact on overall cost in the future.
CONCLUSION
Current evidence establishes a role for the use of robotic surgery in the treatment of gynecologic malignancies, especially with the distinct advantages robotic surgery offers over management by open surgery. Most studies have supported the equivalence of robotic surgery and laparoscopy in many perioperative outcomes, however, robotic surgery may have advantages over laparoscopy in the learning curve required to perform complex gynecologic oncology procedures by a minimally invasive method. The cost of robotic technology remains a potential barrier to universal acceptance of robotic surgery; however, the cost of robotic technology may decrease with increasing utilization. Further research should be implemented to validate the use of robotic surgery in gynecologic malignancies.
